US Bancorp’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $99.3K | Sell |
4,544
-29
| -0.6% | -$603 | ﹤0.01% | 2457 |
|
|
2026
Q1 | $107K | Buy |
4,573
+52
| +1% | +$1.13K | ﹤0.01% | 2350 |
|
|
2025
Q4 | $95K | Hold |
4,521
| – | – | ﹤0.01% | 2399 |
|
|
2025
Q3 | $69.6K | Buy |
4,521
+143
| +3% | +$1.87K | ﹤0.01% | 2515 |
|
|
2025
Q2 | $41K | Sell |
4,378
-677
| -13% | -$7.45K | ﹤0.01% | 2871 |
|
|
2025
Q1 | $62.1K | Sell |
5,055
-300
| -6% | -$4.23K | ﹤0.01% | 2631 |
|
|
2024
Q4 | $70.8K | Sell |
5,355
-2,688
| -33% | -$46K | ﹤0.01% | 2566 |
|
|
2024
Q3 | $155K | Buy |
8,043
+125
| +2% | +$2.58K | ﹤0.01% | 2173 |
|
|
2024
Q2 | $163K | Sell |
7,918
-228
| -3% | -$4.77K | ﹤0.01% | 2097 |
|
|
2024
Q1 | $194K | Buy |
8,146
+416
| +5% | +$9.28K | ﹤0.01% | 2026 |
|
|
2023
Q4 | $167K | Buy |
7,730
+3,083
| +66% | +$47.4K | ﹤0.01% | 2097 |
|
|
2023
Q3 | $67.5K | Buy |
4,647
+177
| +4% | +$3.35K | ﹤0.01% | 2310 |
|
|
2023
Q2 | $93.6K | Sell |
4,470
-73
| -2% | -$1.52K | ﹤0.01% | 2231 |
|
|
2023
Q1 | $95.9K | Buy |
4,543
+213
| +5% | +$5.3K | ﹤0.01% | 2217 |
|
|
2022
Q4 | $110K | Hold |
4,330
| – | – | ﹤0.01% | 2159 |
|
|
2022
Q3 | $104K | Hold |
4,330
| – | – | ﹤0.01% | 2181 |
|
|
2022
Q2 | $83K | Hold |
4,330
| – | – | ﹤0.01% | 2340 |
|
|
2022
Q1 | $75K | Hold |
4,330
| – | – | ﹤0.01% | 2418 |
|
|
2021
Q4 | $95K | Hold |
4,330
| – | – | ﹤0.01% | 2331 |
|
|
2021
Q3 | $83K | Hold |
4,330
| – | – | ﹤0.01% | 2396 |
|
|
2021
Q2 | $74K | Hold |
4,330
| – | – | ﹤0.01% | 2470 |
|
|
2021
Q1 | $97K | Hold |
4,330
| – | – | ﹤0.01% | 2290 |
|
|
2020
Q4 | $96K | Hold |
4,330
| – | – | ﹤0.01% | 2227 |
|
|
2020
Q3 | $64K | Hold |
4,330
| – | – | ﹤0.01% | 2295 |
|
|
2020
Q2 | $64K | Hold |
4,330
| – | – | ﹤0.01% | 2324 |
|
|
2020
Q1 | $48K | Hold |
4,330
| – | – | ﹤0.01% | 2381 |
|
|
2019
Q4 | $38K | Hold |
4,330
| – | – | ﹤0.01% | 2603 |
|
|
2019
Q3 | $32K | Hold |
4,330
| – | – | ﹤0.01% | 2656 |
|
|
2019
Q2 | $40K | Hold |
4,330
| – | – | ﹤0.01% | 2632 |
|
|
2019
Q1 | $23K | Hold |
4,330
| – | – | ﹤0.01% | 2810 |
|
|
2018
Q4 | $19K | Hold |
4,330
| – | – | ﹤0.01% | 2835 |
|
|
2018
Q3 | $35K | Hold |
4,330
| – | – | ﹤0.01% | 2727 |
|
|
2018
Q2 | $30K | Hold |
4,330
| – | – | ﹤0.01% | 2798 |
|
|
2018
Q1 | $62K | Hold |
4,330
| – | – | ﹤0.01% | 2483 |
|
|
2017
Q4 | $38K | Hold |
4,330
| – | – | ﹤0.01% | 2714 |
|
|
2017
Q3 | $51K | Buy |
+4,330
| New | +$53.1K | ﹤0.01% | 2562 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
US Bancorp's SNDX Position: Q2 2026 in Review
US Bancorp reduced its Syndax Pharmaceuticals (SNDX) stake by 0.63% in Q2 2026, selling an estimated $603 and leaving 4,544 shares worth $99.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2457.
US Bancorp first reported a position in SNDX in Q3 2017 and has held it in 36 quarters since. The position peaked at $194K in Q1 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- US Bancorp held 4,544 shares of Syndax Pharmaceuticals worth $99.3K as of Q2 2026.
- US Bancorp sold 29 Syndax Pharmaceuticals shares in Q2 2026, an estimated $603.
- Syndax Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2457 holding.
- US Bancorp first reported a position in Syndax Pharmaceuticals in Q3 2017 and has held it in 36 quarters since.
- US Bancorp's Syndax Pharmaceuticals position peaked at $194K in Q1 2024.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.